| Statin therapy: where are we? Where do we go next? | |
| | |
MedLine Citation:
|
PMID: 11256844 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Statin therapy reduces coronary artery disease morbidity and mortality in primary and secondary prevention trials including patients with elevated and average cholesterol levels. The association between reduction of total or low-density lipoprotein cholesterol and preventive benefit is well established. However, additional risk factors for coronary artery disease need to be incorporated into risk assessment to provide an accurate measure of global risk for use in lifestyle intervention and drug therapy guidelines. Assessment of outcomes in the Air Force/Texas Coronary Atherosclerosis Prevention Study primary prevention trial, which involved patients with average cholesterol levels and reduced high-density lipoprotein cholesterol (HDL-C), suggests the importance of on-treatment values of apolipoproteins B and A-I in predicting first major events in such a population. Other data, including trials of fibrate therapy showing reduction in coronary artery disease events, support the importance of triglycerides and HDL-C in coronary artery disease risk. Challenges for future treatment guidelines include incorporation of emerging and novel risk factors into risk assessment, refinement of global risk measurement, and simplification for application to clinical practice. |
| | |
Authors:
|
A M Gotto |
Related Documents
:
|
14610384 - Are statins indicated for the primary prevention of cad in octogenarians? antagonist vi... 16004894 - Prognostic value of lipoproteins and their relation to inflammatory markers among patie... 3282934 - Lipid and lipoprotein changes in relation to oral contraception and hormonal replacemen... 18823504 - C-reactive protein and coronary heart disease: a critical review. 10211994 - Vascular endothelial growth factor and its receptor, kdr, in human brain tissue after i... 12732604 - Alterations in atrial electrophysiology and tissue structure in a canine model of chron... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: The American journal of cardiology Volume: 87 ISSN: 0002-9149 ISO Abbreviation: Am. J. Cardiol. Publication Date: 2001 Mar |
Date Detail:
|
Created Date: 2001-03-20 Completed Date: 2001-04-05 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0207277 Medline TA: Am J Cardiol Country: United States |
Other Details:
|
Languages: eng Pagination: 13B-18B Citation Subset: AIM; IM |
Affiliation:
|
Weill Medical College of Cornell University, Cornell University, New York, New York 10021, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Cholesterol
/
blood Cholesterol, HDL / blood Clinical Trials as Topic Coronary Disease / blood, etiology, prevention & control* Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use* Hypercholesterolemia / blood, complications, drug therapy* Practice Guidelines as Topic Pravastatin / therapeutic use* Primary Prevention / methods Risk Factors |
| Chemical | |
Reg. No./Substance:
|
0/Cholesterol, HDL; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 57-88-5/Cholesterol; 81093-37-0/Pravastatin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Phase I trial of gemcitabine in patients with advanced pancreatic cancer.
Next Document: Economics of lipid lowering in primary prevention: lessons from the West of Scotland Coronary Preven...